Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of eplontersen in hATTR-PN
2021-001427-40Phase 3Active
- Sponsor
- Ionis Pharmaceuticals
- Start
- Dec 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eplontersen in familial amyloid polyneuropathy (FAP), sponsored by Ionis Pharmaceuticals. Primary endpoint: Change from baseline. Started Dec 2021; status: active.
02
Drugs
eplontersen
03
Conditions
familial amyloid polyneuropathy (FAP)
Beyond the preview
Go deeper on 2021-001427-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001427-40.